Search Results - "Hahne, William F"

Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB by POLLACK, Vincent A, ALVAREZ, Enrique, HAHNE, William F, SENTER, Peter D, JEFFERS, Michael E, LICHENSTEIN, Henri S, LAROCHELLE, William J, KAM FAI TSE, TORGOV, Michael Y, SAM XIE, SHENOY, Suresh G, MACDOUGALL, John R, ARROL, Sharon, HAIHONG ZHONG, GERWIEN, Robert W

“…To investigate the pharmacological properties of the CR011-vcMMAE fully human antibody-drug conjugate (ADC), such as dose titrations, quantitation of the time…”
Get full text

Treatment of Postoperative Nausea and Vomiting with Single Intravenous Doses of Dolasetron Mesylate: A Multicenter Trial by Kovac, Anthony L, Scuderi, Phillip E, Boerner, Thomas F, Chelly, Jacques E, Goldberg, Michael E, Hantler, Charles B, Hahne, William F, Brown, Robert A

“…This study was conducted to determine the efficacy and safety of four intravenous (IV) doses of dolasetron, an investigational 5-HT3 receptor antagonist, for…”
Get full text

Single-Dose Prevention or Short-Term Treatment with Fibroblast Growth Factor-20 (CG53135-05) Reduces the Severity and Duration of Oral Mucositis by Alvarez, Enrique, Gerlach, Valerie L., Gerwien, Robert W., Fey, Edward G., Watkins, Brynmor A., Hahne, William F., Sonis, Stephen T.

“…Oral mucositis (OM) is a treatment-limiting condition associated with myelosupressive chemotherapy and radiation therapy. The objective of this study was to…”
Get full text

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis by HARMAN, G. S, OMURA, G. A, RYAN, K, HAINSWORTH, J. D, CRAMER, M. R, HAHNE, W. F

“…Intravenous dolasetron has been shown to be an effective antiemetic agent in patients receiving high-dose cisplatin-containing chemotherapy. Previous studies…”
Get full text

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1 by Dimmitt, Dan C., Choo, Youn Sung, Martin, Lorene A., Arumugham, Thangam, Hahne, William F., Weir, Scott J.

“…In this first part of a two‐part investigation, the intravenous dose proportionality of dolasetron mesylate, a 5‐HT3 receptor antagonist, and the absolute…”
Get full text

Oral Dolasetron Mesylate for Prevention of Postoperative Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Study by Diemunsch, Pierre, Korttila, Kari, Leeser, Jos, Helmers, J.H.J.H, Wilkey, Brian, Navé, Stephane, Radke, Anton J, Hahne, William F, Brown, Robert A

“…Study Objective: To examine the safety and effectiveness of a range of single oral doses of dolasetron mesylate for the prevention of postoperative nausea and…”
Get full text

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting: Pooled analysis of 14 clinical trials by WHITMORE, J. B, KRIS, M. G, HESKETH, P. J, GROTE, T. H, DUBOIS, D. M, CRAMER, M. B, HAHNE, W. F

“…Dolasetron mesilate is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting. For the majority of…”
Get full text

Stereochemical control of the ynamine-Claisen rearrangement by Bartlett, Paul A, Hahne, William F

Get full text

Stereochemistry of the reaction of dimethyl sulfoxide with dichloro(glycinato)platinate(II) and similar amino acid complexes by Erickson, Luther E, Hahne, William F

Get full text

Intravenous Dolasetron for the Prevention of Postoperative Nausea and Vomiting After Outpatient Laparoscopic Gynecologic Surgery by Graczyk, Sarena G., McKenzie, Ray, Kallar, Surindar, Hickok, Charles B., Melson, Timothy, Morrill, Bruce, Hahne, William F., Brown, Robert A.

“…The newer 5-hydroxytryptamine type 3 (5-HT3) antagonists are sometimes considered for routine prophylaxis of postoperative nausea and vomiting (PONV) in…”
Get full text

Randomized, double blind, dose‐response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy by Rubenstein, Edward B, Gralla, Richard J., Hainsworth, John D., Hesketh, Paul J., Grote, Thomas H., Modiano, Manuel R., Khojasteh, Ali, Kalman, Leonard A., Benedict, Claude R., Hahne, William F.

“…BACKGROUND This double blind parallel group study assessed the acute antiemetic efficacy of four oral doses of dolasetron mesylate in cancer patients receiving…”
Get full text

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin by Kris, M G, Grunberg, S M, Gralla, R J, Baltzer, L, Zaretsky, S A, Lifsey, D, Tyson, L B, Schmidt, L, Hahne, W F

“…This dose-ranging trial of intravenous dolasetron mesylate (MDL73,147EF) was performed to determine its adverse and antiemetic effects in patients receiving…”
Get more information

A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers by Hunt, T L, Cramer, M, Shah, A, Stewart, W, Benedict, C R, Hahne, W F

“…The safety and tolerability of dolasetron mesylate, a potent and selective 5-HT3 receptor antagonist, were evaluated after single intravenous doses in healthy…”
Get more information

Intravenous Dolasetron for the Prevention of Postoperative Nausea and Vomiting After Outpatient Laparoscopic Gynecologic Surgery by Graczyk, Sarena G., McKenzie, Ray, Kallar, Surindar, Hickok, Charles B., Melson, Timothy, Morrill, Bruce, Hahne, William F., Brown, Robert A.

Get full text

Treatment of Postoperative Nausea and Vomiting with Single Intravenous Doses of Dolasetron Mesylate: A Multicenter Trial by Kovac, Anthony L., Scuderi, Phillip E., Boerner, Thomas F., Chelly, Jacques E., Goldberg, Michael E., Hantler, Charles B., Hahne, William F., Brown, Robert A.

Get full text

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting by Whitmore, J. B., Kris, Mark G., Hesketh, Paul J., Grote, Thomas H., DuBois, Dawn M., Cramer, Michael B., Hahne, William F.

Get full text

Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery by Diemunsch, Pierre, D'Hollander, Alain, Paxton, Lionel, Schoeffler, Pierre, Wessel, Pierrette, Navé, Stephane, Brown, Robert A., Hahne, William F.

“…Study Objective: To evaluate a range of doses of intravenous (IV) dolasetron mesilate, in preventing postoperative nausea and vomiting (PONV). Design:…”
Get full text

Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy by Lippert, C L, Dimmitt, D C, Martin, L, Cramer, M B, Plezia, P, Hahne, W F

“…Dolasetron mesylate (MDL 73,147, Anzemet, Hoechst Marion Roussel, Kansas City, MO) is a 5-HT ( 3 ) receptor antagonist undergoing clinical evaluation as an…”
Get more information

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide by HESKETH, P. J, GANDARA, D. R, HESKETH, A. M, FACADA, A, PEREZ, E. A, WEBBER, L. M, MARTIN, L. A, CRAMER, M. B, HAHNE, W. F

“…Selective 5-HT3 antagonists have proven to be safe and effective for the prevention of chemotherapy-induced nausea and vomiting. Dolasetron is a new highly…”
Get full text

Single-dose, placebo-controlled, phase I study of oral dolasetron by Dixon, R M, Cramer, M, Shah, A K, Whitmore, J, Benedict, C R, Hahne, W F

“…To evaluate the safety, tolerability, and pharmacokinetics of single, escalating doses of oral dolasetron mesylate, a new 5-HT3 receptor antagonist…”
Get more information